Medical Insights from Industry

RSS

"Insights from Industry" is a dynamic series of interviews at the cutting edge of the medical industry. Every interviewee is a leader in their particular field and is handpicked to give an informative and accessible insight into their chosen field. These interviews are guaranteed to keep you in the know in a rapidly changing industry.

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Personalized knee replacement: an interview with Dr Martin, Preferred Orthopedics of the Palm Beaches

Knee replacement surgery has traditionally been performed using off-the-shelf implants because of the limitations of technology. As with most industries, evolution does occur.

25 Apr 2013

Rheumatoid arthritis diagnosis: an interview with Dr. Stan Naides, Medical Director, Quest Diagnostics

Rheumatoid arthritis (RA) is an autoimmune disorder that can cause debilitating joint damage. In cases of RA, the immune system attacks the body’s own tissues, especially the membranes that line the joints. As a result, fluid builds up in the joints, causing pain and systemic inflammation, leading to joint destruction if untreated.

From Quest Diagnostics 23 Apr 2013

Obstructive salivary gland disease treatment: an interview with Thomas Cherry, Cook Medical

Everyone is familiar with urinary stones (kidney stones). The same thing can actually happen in your salivary ducts. These types of stones and strictures occur not nearly as frequently as kidney stones but they still occur quite often. The latest data we have seen showed about 1 in 5,000 patients actually have some type of obstructive salivary duct disorder.

From COOK MEDICAL INC. 19 Apr 2013

Social care: an interview with Neil Matthewman, CEO Community Integrated Care

Community Integrated Care is one of the UK’s largest social and health care charities. We support over 2500 people with learning disabilities, mental health concerns, autism and age-related needs, living across England and Scotland.

From Community Integrated Care 17 Apr 2013

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.

16 Apr 2013

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Ulcerative colitis (UC) and Crohn’s disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.

From Takeda 3 Apr 2013

Handheld ultrasound devices: an interview with Warren Ortmann, Signostics

Ultrasound devices use sound waves to image the organs of the body safely, without the use of radiation. The sound waves are produced by applying a current to a piezoelectric crystal housed in a transducer. The crystal alters shape and creates a sound wave.

3 Apr 2013

Biological markers for triple-negative breast cancer (TNBC): an interview with Alexandre Templier, CEO of Quinten

Triple negative breast cancer (TNBC) is a type of cancer that has none of the three markers that are currently used for targeted chemotherapy. These markers are estrogen receptor (ER), progesterone receptor (PR) and HER2.

27 Mar 2013

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

Chronic hepatitis C infection is one of the most frequent chronic infectious diseases worldwide. The WHO estimates that 150 million people worldwide are chronically infected with the hepatitis C virus (HCV).

20 Mar 2013

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor, or TKI, that is being investigated for use in patients with advanced renal cell carcinoma (RCC), or kidney cancer.

19 Mar 2013

Non-surgical weight loss devices: an interview with Richard Thompson, CEO ReShape Medical

Only a very few percent of patients that qualify for weight loss surgery actually choose to have it. It is a last resort and most patients do not see themselves as ready to give up. On the other hand, diet and exercise rarely work well and patients are looking for some extra help in their quest to lower their weight. A reversible, non-surgical approach has a lot of appeal to these patients.

15 Mar 2013

Non-invasive prenatal genetic screening: an interview with Dr. Charles Strom, Senior Medical Director, Quest Diagnostics

A new category of non-invasive genetic screening tests is gaining a great deal of interest in the medical field – including from Quest Diagnostics -- for its potential to help screen women during pregnancy for genetic abnormalities known as trisomies, the most common of which is Down syndrome.

From Quest Diagnostics 13 Mar 2013

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Antibodies and in the case of Ablynx, Nanobodies, can be raised and selected to bind with high affinity selectively to cancer cells in a tumour. Cancer cells are exquisitely sensitive to certain toxins such as the PBDs produced by Spirogen.

12 Mar 2013

Medical Adhesives for Reusable or Disposable Medical Devices

An interview with Robert Michaels, discussing the major challenges faced by engineers designing medical devices and the development of new medical adhesives.

From Master Bond Inc. 28 Feb 2013

Breast cancer tests: an interview with Dr Steven Quay, CEO of Atossa Genetics

Breast cancer is a major concern throughout the world. It is the number 1 cancer among women and in the Western world it generates approximately one new case per minute: 24 hours a day 7 days a week.

22 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

Otolaryngology, head and neck surgery: an interview with Thomas Cherry, Cook Medical

Cook Medical is the world’s largest privately held medical device manufacturer. The ENT division is Cook’s 10th business unit/clinical division and we are excited to meet the needs of ENT patients.

From COOK MEDICAL INC. 18 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Marblar is gamifying the process of technology transfer. We post technology on our platform in the form of a challenge, and the Marblar community then competes to uncover new problems these technologies could solve – thereby discovering new market applications for these technologies.

31 Jan 2013